India likely to have concerns over Trump’s proposed pharma tariffs, says Marco Rubio
US Secretary of State says the issue did not come up in detail during his meeting with External Affairs Minister S. Jaishankar in Manila, even as proposed tariffs on imported medicines raise concerns for Indian drug exporters.
India is likely to have concerns over US President Donald Trump's proposal to impose tariffs on imported pharmaceutical products, US Secretary of State Marco Rubio said, acknowledging the potential implications for one of the world's largest suppliers of generic medicines. Rubio, however, said the issue was not discussed in detail during his meeting with External Affairs Minister S. Jaishankar on the sidelines of regional meetings in Manila.
Speaking to reporters after the bilateral meeting, Rubio said he would expect India to be concerned by the proposed tariff measures but indicated that pharmaceuticals did not feature prominently in his discussions with Jaishankar. The comments come as the Trump administration weighs higher import duties on medicines as part of a broader push to expand domestic manufacturing in the United States.
Tariff proposal under industry watch
The proposed tariff plan has drawn close attention from the pharmaceutical industry, given India's position as the largest supplier of generic medicines to the US by volume. According to industry players, any increase in import duties could have implications for export competitiveness, supply chains and pricing across the healthcare sector, industry experts have said.
India's pharmaceutical exports to the US account for a significant share of the country's overseas drug shipments, with Indian manufacturers supplying affordable generic medicines across a wide range of therapeutic segments. The US also remains one of the most important markets for Indian drugmakers, making developments in American trade policy a key focus for the industry.
Trade ties remain in focus
While trade issues formed part of the broader engagement between the two leaders, Rubio suggested that the proposed pharmaceutical tariffs were not examined in detail during the meeting. India and the US continue to engage across a wide range of strategic areas, including trade, defence, technology, energy and critical minerals.
Rubio's remarks come at a time when Indian pharmaceutical companies are closely tracking developments in Washington for greater clarity on the proposed tariff framework. Any final decision on import duties could influence export strategies and investment plans for companies with significant exposure to the US market, while also shaping the broader trajectory of India-US trade in pharmaceuticals.